EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.

ABSTRACT:

Objectives

The objectives of this study were to investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and to identify factors associated with FHS after treatment.

Methods

Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belimumab (N = 1684) were utilized. FHS was defined as a response of no problems in all five EQ-5D-3L dimensions, yielding an index score of 1. The Pearson's χ2 or Fisher's exact test was employed for comparisons, and logistic regression for adjustments and assessment of independence.

Results

We demonstrated higher EQ-5D-3L FHS frequencies among patients given standard therapy (ST) plus the licensed belimumab dose vs ST alone (26.1% vs 19.4%; P = 0.001; week 52), and within SRI-4

SUBMITTER: Lindblom J 

PROVIDER: S-EPMC8487305 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature